e-therapeutics plc
ETXPF
$0.13
-$0.01-7.14%
OTC PK
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -37.72% | -19.50% | -1.63% | 5.35% | 8.46% |
| Total Depreciation and Amortization | 2.64% | 11.22% | 18.25% | 47.65% | 117.94% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -185.42% | -213.55% | -253.20% | -131.28% | -27.98% |
| Change in Net Operating Assets | 1,066.28% | 427.98% | 205.02% | 580.88% | -80.10% |
| Cash from Operations | -37.33% | -17.43% | 0.27% | 6.26% | 7.50% |
| Capital Expenditure | -263.65% | -32.78% | 84.30% | 65.55% | 41.38% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.94% | -94.72% | -87.15% | 382.39% | 246.24% |
| Cash from Investing | -98.52% | -96.00% | -87.23% | 368.56% | 244.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.28% | -91.36% | -362.31% | -281.54% | -200.77% |
| Issuance of Common Stock | -99.72% | 0.22% | 63,952.38% | 23.96% | -37.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -102.91% | -5.76% | 1,530.67% | -4.86% | -50.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -155.09% | -152.89% | 157.39% | 1,823.92% | 265.05% |